MartinE.HaleMD

PubMed

• 25 citations
  Low-dose cyclobenzaprine versus combination therapy with ibuprofen for acute neck or back pain with muscle spasm: A randomized trial
  Martin K. Childers, David G. Borenstein, Richard L. Brown, Steven Gershon, Martin E. Hale
  Current Medical Research and Opinion. 2005-08-23
• 127 citations
  Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, random...
  Martin E. Hale, Harry Ahdieh, Tina Ma, Richard Rauck
  The Journal of Pain. 2007-02-01
• 103 citations
  Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.
  Martin E. Hale, Roy Fleischmann, Robert T. Salzman, Jim M. Wild, Tad Iwan
  The Clinical Journal of Pain. 1999-09-01

Journal Articles

• Long-Term Safety and Analgesic Efficacy of Buprenorphine Buccal Film in Patients with Moderate-toSevere Chronic Pain Requiring Around-the-Clock Opioids  
  Hale, M.; Urdaneta, V.; Kirby, T.; Xiang, Q.; Rauck, R., Journal of Pain Research, 1/1/2017
• Naldemedine Versus Placebo for Opioid-Induced Constipation (COMPOSE-1 and COMPOSE-2): Two Multicentre, Phase 3, Double-Blind, Randomised, Parallel-Group Trials  
  Hale, M.; Wild, J.; Reddy, J.; Yamada, T.; Camilo, J., The Lancet Gastroenterology & Hepatology, 1/1/2017
• 6-Month, Open-Label Study of Hydrocodone Extended-Release Formulated With Abuse-Deterrence Technology: Safety, Maintenance of Analgesia, and Abuse Potential  
  Hale, M.; Ma, Y.; Malamut, R, Journal of Opioid Management, 1/1/2016
• Evaluation of Quality of Life, Functioning, Disability, and Work/School Productivity Following Treatment With an Extended-Release Hydrocodone Tablet Formulated With Ab...  
  Hale, M.; Zimmerman, T,; Ma, Y.; Malamut, R., Pain Practice, 1/1/2016
• Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Cancer Pain Receiving Opioid Therapy: Results From Two...  
  Hale, M.; Wild, J.; Reddy, J.; Yamada, T.; Ferreira, A.; Camilo, J., Gastroenterology, 1/1/2016
• Efficacy and Safety of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Patients with Moderate-to-Severe Chronic Low Back Pain  
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; et al., Journal of Opioid Management, 1/1/2015
• A Randomized Double-Blind, Placebo-Controlled Efficacy and Safety Study of ALO-02 (Extended Release Oxycodone Surrounding Sequestered Naltrexone) for Moderate-to-Sever...  
  Rauck, R.; Hale, M.E.; Bass, A.; Bramson, C.; Pixton, G.; Wilson, J.; Setnik, B.; Meisner, P.; Sommerville, K.W.; Malhotra, B.K.; Wolfram, G., Pain, 1/1/2015
• A 12-Month, Open-Label Assessment of the Long-Term Safety and Abuse Potential of an ExtendedRelease Hydrocodone Formulation With Abuse-Deterrence Technology in Chronic...  
  Hale, M.; Zimmerman, T,; Ma, Y.; Malamut, R., Journal of Opioid Management, 1/1/2015
• Efficacy and Tolerability of a Hydrocodone Extended-Release Tablet Formulated With AbuseDeterrence Technology for the Treatment of Moderate to Severe Chronic Pain in P...  
  Hale, M.E.; Laudadio, C.; Yang, R.;Narayana, A.; Malamut, R., Journal of Pain Research, 1/1/2015
• Efficacy and Safety of Hydrocodone Extended-Release Tablets Formulated with an Abuse-Deterrence Technology Platform for the Treatment of Moderate to Severe Pain in Pat...  
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; Malamut, R, J Pain, 1/1/2015
• Low Risk of Diversion in a Randomized, Double-Blind, Placebo-Controlled Study of Extended-Release Hydrocodone Tablets Formulated with Abuse-Deterrence Technology for t...  
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; Malamut, R., J Pain, 1/1/2015
• Low Risk of Aberrant DrugRelated Behavior Observed During a 12-Month Open-Label Study in Patients Taking an Extended-Release Hydrocodone Tablet, Formulated with Oragua...  
  Hale, M.; Zimmerman, T,; Ma, Y.; Malamut, R., J Pain, 1/1/2014
• Long-Term Safety and Maintenance of Analgesia with an Extended-Release Hydrocodone Tablet Formulated with Oraguard(TM) Technology During a 12-Month Open-Label Study in...  
  Hale, M.; Zimmerman, T,; Ma, Y.; Malamut, R., J Pain, 1/1/2014
• Evaluation of Work/School Productivity Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Oraguard(TM) Technology: A 12-Month Open-Label S...  
  Hale, M.; Zimmerman, T,; Ma, Y.; White, R.; Malamut, R., J Pain, 1/1/2014
• Efficacy and Safety of ALO-02, an Extended-Release Oxycodone Surrounding Sequestered Naltrexone, in the Treatment of Moderateto-Severe Chronic Low Back Pain  
  Rauck, R.; Hale, M.; Bass,A.;;Bramson, C.; Pixton, G.; Setnik, B.; Meisner, P.; Sommerville, K., J Pain, 1/1/2014
• A LongTerm, Open-Label Study of Single-Entity Hydrocodone Bitartrate Extended Release for the Treatment of Moderate to Severe Chronic Pain  
  Nalamachu, S.; Rauck, R.; Hale, M.; Florete, O.; Robinson, C.; Farr, S., J Pain Research, 1/1/2014
• Hydromorphone Extended Release for Neuropathic and Non-Neuropathic/Nociceptive Chronic Low Back Pain: A Post Hoc Analysis of Data from a Randomized, Multicenter, Doubl...  
  Nalamachu, S.; Hale, M.; Khan, A., Journal of Opioid Management, 1/1/2014
• Evaluation of Quality of Life, Functioning, and Disability Following Treatment with an Extended-Release Hydrocodone Tablet Formulated with Oraguard(TM) Technology: A 1...  
  Hale, M.; Zimmerman, T,; Ma, Y.; Malamut, R., J Pain, 1/1/2014
• Effectiveness and Gastrointestinal Tolerability During Conversion and Titration with Once-Daily OROS(R) Hydromorphone ER in Opioid-Tolerant Patients with Chronic Low B...  
  Hale, M.E.; Nalamachu, S.; Khan, A.; Kutch, M, J. Pain Research, 1/1/2013
• Safety and Tolerability of Once-Daily OROS(R) Hydromorphone Extended-Release in Opioid-Tolerant Adults with Moderate-to-Severe Chronic Cancer and Noncancer Pain: Poole...  
  Nalamachu, S.; Kutch, M; Hale, M.E., J. Pain Symptom Manage, 1/1/2012
• Safety and Tolerability of OROS(R) Hydromorphone ER in Adults with Chronic Noncancer and Cancer Pain: Pooled Analysis of 13 Studies  
  Hale, M.E.; Wallace, M.S.; Taylor, D.R.; Kutch, M.; Nalamachu, S, J. Opioid Management, 1/1/2012
• An Overview of the Clinical Study and Use of Butrans(R) (buprenorphine) Transdermal System in Opioid-Experienced Patients  
  Hale, M.E., Pain Med News, 1/1/2012
• Efficacy and Safety of Buprenorphine Transdermal System (BTDS) for Chronic Moderate to Severe Low Back Pain: A Randomized, Double-blind Study  
  Steiner, D.; Munera, C.; Hale, M.; Ripa, S.; Landau, C., J. Pain, 1/1/2011
• Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules in Patients with Chronic Osteoarthritis Pain  
  Katz, N.; Hale, M.; Morris, D.; Stauffer, J., Postgraduate Medicine, 1/1/2010
• Once-Daily OROS(R) Hydromorphone ER Compared with Placebo in Opioid-Tolerant Patients with Chronic Low Back Pain  
  Hale, M.; Khan, A.; Kutch, M.; Li, S., Current Medical Research and Opinion, 1/1/2010
• Join now to see all

Books/Book Chapters

• The Essence of Analgesia and Analgesics 
  Chapter: New and Emerging Analgesics 
  Hale, M.Editors: Sinatra, R.; Jahr, J.; Watkins-Pitchford, J.Cambridge University Press, New York2010

Abstracts/Posters

• Wild, J.; Webster, L.; Yamada, T.; Hale, M., Annual Academy of Managed Care Pharmacy (AMCP) Nexus, Orlando, FL, 1/1/2018
• Safety and Efficacy of Naldemedine in the Treatment of Opioid-Induced Constipation in Chronic Non-Cancer Pain in Subjects With or Without Inadequate Response to Laxatives
  Tack, J.; Hale, M.; Yamada, T.; Wild, J., 26th Annual United European Gastroenterology Week, Vienna, Austria, 1/1/2018
• Naldemedine Is Effective in the Treatment of Opioid-induced Constipation in Chronic Non-Cancer Pain in Subjects With or Without Inadequate Response to Laxatives
  Tack, J.; Hale, M.; Krauter, E.; Yamada, T.; Yokota, T,; Wild, J., 83rd Annual Scientific Meeting of the American College of Gastroenterology, Philadelphia, PA, 1/1/2018
• A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioidinduced Constipation in Patients With Chronic Non-Cancer Pain...
  Webster, L.; Hale, M.; Yamada, T.; Wild, J., International Association for the Study of Pain, Boston, MA, 1/1/2018
• Effect of Naldemedine on Frequency of Spontaneous Bowel Movements and Associated Symptoms of Opioid Induced Constipation
  Wild, J.; Yamada, T.; Ferreira, A.; Hale, M., PAINWeek, Las Vegas, NV, 1/1/2018
• Effect of Naldemedine on Frequency of Spontaneous Bowel Movements and Associated Symptoms
  Wild, J.; Hale, M.; Yamada, T.; Camilo, J.; Ferreira, A., American College of Gastroenterology (ACG)-World Congress of Gastroenterology, Orlando, FL, 1/1/2017
• Novel Design to Evaluate the Efficacy and Safety of an Abuse-Deterrent, Extended-Release Oxycodone Product Candidate in Patients With Moderate-to-Severe Chronic Low Ba...
  Rauck, R.; Markman, J.; Nalamachu, S.; Hale, M.; Dayno, J.; Niebler, G.; Lawler, J.; Coyle, E.; O�Brien-Giemza, J.; Katz, N, American Pain Society 36th Annual Meeting, Pittsburgh, PA, 1/1/2017
• Onset of Action of Naldemedine in the Treatment of Opioid-induced Constipation in Patients With Chronic Non-cancer Pain: Results From Two Randomized, Placebo-controlle...
  Wild, J.; Hale, M.; Reddy, J.; Yamada, T.; Ferreira, A, 81st Annual Scientific Meeting of the American College of Gastroenterology, Orlando, FL, 1/1/2016
• Efficacy and Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Chronic Non-Cancer Pain Receiving Opioid Therapy: Results From 2 P...
  Hale, M.; Wild, J.; Reddy, J.; Yamada, T.; Ferreira, A., PAINWeek, 24th Annual United European Gastroenterology Week, Las Vegas, NV, 2016; Vienna, Austria, 2016, 1/1/2016
• Long-Term Safety and Analgesic Efficacy of Buprenorphine Buccal Film in Patients With Moderate-toSevere Chronic Pain Requiring Around-the-Clock Opioids
  Hale, M.; Urdaneta, V.; Kirby, M.T.; Xiang, Q.; Rauck,R, International Conference on Opioids, Boston, MA, 1/1/2016
• Hydrocodone ExtendedRelease Tablets Formulated With an Abuse-Deterrence Technology Platform for Treatment of Moderate to Severe Pain: Efficacy and Safety in Patients W...
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; Malamut, R, 26th Annual Clinical Meeting, Washington, DC, 1/1/2015
• Risk of Diversion and Loss of Hydrocodone Extended-Release Tablets Formulated With Abuse-Deterrence Technology: Randomized, Double-Blind, Placebo-Controlled Study in P...
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; Malamut, R, 26th Annual Clinical Meeting, Washington, DC, 1/1/2015
• Phase 3 Study of Hydrocodone Extended-Release Tablets Formulated With an Abuse-Deterrence Technology Platform for Moderate to Severe Pain: Efficacy and Safety in Patie...
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; Malamut, R, PainWEEK, Las Vegas, NV, 1/1/2015
• Randomized, Double-Blind, Placebo-Controlled Study Assessing Risk of Diversion and Loss of ExtendedRelease Hydrocodone Tablets Formulated with Abuse-Deterrence Technol...
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; Malamut, R, PainWEEK, Las Vegas, NV, 1/1/2015
• Efficacy and Safety of Hydrocodone Extended-Release Tablets Formulated with an Abuse-Deterrence Technology Platform for the Treatment of Moderate to Severe Pain in Pat...
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; Malamut, R, American Pain Society 34th Annual Meeting, San Diego, CA, 1/1/2015
• Low Risk of Diversion in a Randomized, Double-Blind, Placebo-Controlled Study of Extended-Release Hydrocodone Tablets Formulated with Abuse-Deterrence Technology for t...
  Hale, M.E.; Zimmerman, T.R.; Eyal, E.; Malamut, R, American Pain Society 34th Annual Meeting, San Diego, CA, 1/1/2015
• Efficacy of Extended-Release Hydrocodone Tablets Formulated with Oraguard(TM) Technology for the Treatment of Moderate to Severe Pain in Patients with Chronic Low Back...
  Hale, M.; Narayana,A.; Zimmerman, T.; Eyal,E.; Malamut, R, EFIC, Buenos Aires, Argentina, 1/1/2014
• Safety and Tolerability of Extended-Release Hydrocodone Tablets Formulated with Oraguard(TM) Technology for the Treatment of Moderate to Severe Pain in Patients with C...
  Hale, M.; Narayana,A.; Zimmerman, T.; Eyal,E.; Malamut, R., EFIC, Buenos Aires, Argentina, 1/1/2014
• Evaluation of Quality of Life, Functioning, and Disability Following Treatment With an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology:...
  Hale, M.E.; Zimmerman, T.R.; Ma, Y.; Malamut, R, American Academy of Family Physicians Assembly, Washington, D.C., 1/1/2014
• Long-Term Safety and Maintenance of Analgesia With an Extended-Release Hydrocodone Tablet Formulated With Abuse-Deterrence Technology During a 12-Month Open-Label Stud...
  Hale, M.E.; Zimmerman, T.R.; Ma, Y.; Malamut, R., American Academy of Family Physicians Assembly, Washington, D.C., 1/1/2014
• Evaluation of Work/School Productivity Following Treatment With an Extended-Release Hydrocodone Tablet Formulated With Abuse-Deterrence Technology: a 12-Month Open-Lab...
  Hale, M.E.; Zimmerman, T.R.; Ma, Y.; White, R.; Malamut, R., American Academy of Family Physicians Assembly, Washington, D.C., 1/1/2014
• Low Risk of Aberrant DrugRelated Behavior Observed During a 12-Month Open-Label Study in Patients Taking an Extended-Release Hydrocodone Tablet, Formulated With AbuseD...
  Hale, M.E.; Zimmerman, T.R.; Ma, Y.; Malamut, R, American Academy of Family Physicians Assembly, Washington, D.C., 1/1/2014
• A 12-Month Open-Label Study of an Extended-Release Hydrocodone Formulation With AbuseDeterrence Properties in Patients With Chronic Pain
  Hale, M.E.; Zimmerman, T.R.; Ma, Y.; Malamut, R, American Academy of Family Physicians Assembly, Washington, D.C., 1/1/2014
• Evaluation of Quality of Life, Functioning, and Disability Following Treatment With an Extended-Release Hydrocodone Tablet Formulated with Abuse-Deterrence Technology:...
  Hale, M.E.; Zimmerman, T.R.; Ma, Y.; Malamut, R, PAINWeek, Las Vegas, NV, 1/1/2014
• Long-Term Safety and Maintenance of Analgesia With an Extended-Release Hydrocodone Tablet Formulated With Abuse-Deterrence Technology During a 12-Month Open-Label Stud...
  Hale, M.E.; Zimmerman, T.R.; Ma, Y.; Malamut, R., PAINWeek, Las Vegas, NV, 1/1/2014
• Join now to see all

Lectures

• A Buprenorphine Transdermal Delivery System for the Treatment of Chronic Pain 
  Mumbai, Hyderabad, Chennai and Delhi, 2016; Barranquilla, Colombia, 2017 - 1/1/2017
• Update on the State of Medical Cannabis in the United States 
  Orlando, FL - 1/1/2017
• Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Subjects With Chronic Non-Cancer Pain Receiving Opioid Therapy: Results From Two... 
  San Diego, CA - 1/1/2016
• Opioid Abuse Deterrent Products 
  Orlando, FL - 1/1/2016
• Chronic Musculoskeletal Pain: Centrally-Acting Analgesia Buprenorphine at Low Concentrations 
  Acapulco, Mexico - 1/1/2015
• Teva CNS 
  Miami, FL, 2012; San Diego, CA, 2012 - 1/1/2012
• Clinical Approach to Pain Management in the Chronic Pain Patient 
  Nova-Southeastern University School of Medicine, Davie, FL, 2011; Florida Society of Pain Management - 1/1/2011
• Evidence-based Non-Controlled Pharmaceutical Pain Treatments 
  Orlando, FL - 1/1/2011
• Evidence-based NonPharmacological Pain Treatments 
  Orlando, FL - 1/1/2011
• Covidien Meet the Expert 
  Baltimore, MD - 1/1/2010
• Butrans(TM) Product Theater 
  Multiple locations - 1/1/2010
• Role of the Orthopaedist in Pain Management 
  San Francisco, CA - 1/1./2001
• Training the Trainers 
  Miami, FL - 1/10/2008
• Osteoarthritis and Chronic Pain 
  Miami, FL - 1/10/2008
• My Clinical Experience with Restiva 
  Miami, FL - 1/10/2008
• Join now to see all